BOISE, Idaho, Feb. 03, 2016 -- Micron Technology, Inc. (NASDAQ:MU), will host an analyst conference on Friday, Feb. 12, 2016. Presentations by CEO Mark Durcan and other Micron officers will start at 8 a.m. MT. The company will webcast the analyst meeting 8 a.m. to 11 a.m. MT at http://www.micron.com/investors/conference. A replay will be available via the Website until March 12, 2016.
Micron Technology, Inc., is a global leader in advanced semiconductor systems. Micron’s broad portfolio of high-performance memory technologies—including DRAM, NAND and NOR Flash—is the basis for solid state drives, modules, multichip packages and other system solutions. Backed by more than 35 years of technology leadership, Micron’s memory solutions enable the world’s most innovative computing, consumer, enterprise storage, networking, mobile, embedded and automotive applications. Micron’s common stock is traded on the NASDAQ under the MU symbol. To learn more about Micron Technology, Inc., visit www.micron.com.
Micron and the Micron orbit logo are trademarks of Micron Technology, Inc. All other trademarks are the property of their respective owners.
Contacts: Ivan Donaldson Investor Relations [email protected] (208) 368-4093 Daniel Francisco Media Relations [email protected] (208) 368-5584


Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 



